Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: **Dr. John W. Holaday, Ph.D.**		
2. Your Title: **CEO & Chairman**		
3. The Entity(ies) You are Representing: **DisposeRx, Inc.**		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	**Yes**	**No** X
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2015. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature: 

Date: March 17th 2018

DisposeRx®
Solving the problem of drug disposal

March 19, 2018

Dr. John W. Holaday, Ph.D.

John W. Holaday, Ph.D. (Chairman & Co-founder) is a seasoned entrepreneur and scientist with decades of experience in neuroscience, oncology and immunology. John was the former CEO of QRxPharma Limited (QRX-ASX); co-founder of Medicis (MRX-NYSE); EntreMed (ENMD-NASDAQ) CEO. He is Co-founder and Executive Chairman of ExoCyte Therapeutics, and Director of Pixspan, CytImmune Sciences and Accelovance. Dr. Holaday obtained a BS and MS from the University of Alabama, and PhD with honors from the University of California, San Francisco School of Medicine. He is a Fellow in the American College of NeuropsychoPharmacology (FACNP) and a Fellow in Critical Care Medicine (FCCM). He served at the Walter Reed Army Institute of Research (WRAIR) as Captain, US Army, and as a Presidential Appointee, Chair Neuropharmacology Branch at WRAIR. Dr. Holaday was Professor of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine, and remains as Adj. Professor of Psychiatry, Uniformed Services Univ. of Health Sciences. He raised over $500M for his companies with exits or market capitalizations of over $3 billion. Dr. Holaday was inducted into the E&Y Entrepreneur of the Year 2006 Hall of Fame and served on the advisory board for E&Y for several years. He has received numerous honors and awards, including the Algernon Sydney Sullivan Award as outstanding Alumnus, University of Alabama. John holds over 90 patents and has published over 230 scientific articles and five books.

JOHN W. HOLADAY, PhD, FACNP, FCCM

6502 Hillmead Rd.
Bethesda, MD 20817
johnholaday@mac.com

EDUCATION

University of California San Francisco, CA	Ph.D. (1977) honors Pharmacology
US Army Medical Field Service School Ft. Sam Houston, TX	Honor Graduate (1968)
University of Alabama Tuscaloosa, AL	M.S. (1969) Molecular Biology
University of Alabama Tuscaloosa, AL	B.S. (1966) Biology & Chemistry

EXECUTIVE EXPERIENCE

DisposeRx Co-founder, Chairman and CEO	July, 2015 - present
ExoCyte Therapeutics Co-founder & Executive Chairman	April 2014 - present
QRxPharma Managing Director, President and CEO Founding Director	April 2007 to August 2014
MaxCyte, Inc. Co-founder and Chairman	Mar 1998 to January 2003
EntreMed, Inc. Co-founder Chairman & Chief Executive Officer	Nov 1992 to January 2003
Medicis Pharmaceutical Corporation Senior Vice President for Research & Development, Scientific Director & Co-founder	May 1989-Aug 1992

BOARD CHAIR OR MEMBERSHIP

Pixspan, Inc November 2010 to Present
Director

CytImmune Sciences, Inc. May 1997 to Present
Director

Accelovance, Inc. January 2005 to Present
Director

Neuren Pharmaceuticals Limited November 2009 to 2013
Director

HarVest Bank of Maryland Dec 2003 to Dec 2012
Founding Chairman, member of Board

VOLUNTARY ORGANIZATIONS

Maryland Higher Education Commission July 2015 - Present
Commissioner, Appointed by Gov. Hogan
to oversee all academic institutions in the state

Carnegie Institute of Science Board April 2009 - Present
Math for America, DC

John F. Kennedy Center for the Performing Arts February, 2015 - Present
Circles Board

Chairman, BioScience Alliance April 2001 – April 2004
Technology Council of Maryland

University of Alabama, College of Arts & Sciences January 1998 - Present
Leadership Board

University of Maryland Biotechnology Institute January 2001 –January 2009
Board of Visitors

ACADEMIC/GOVERNMENT APPOINTMENTS

Uniformed Services University of the Health Sciences

Adjunct Professor Psychiatry and Pharmacology — June 1979 - Present

The Johns Hopkins University School of Medicine — July 1990- July 1996
Adjunct Associate Professor
of Anesthesiology and Critical Care Medicine

University of Connecticut Health Center School of Medicine — December, 1991 - 1996
Department of Surgery
Clinical Assistant Professor of Surgery

University of California San Francisco School of Medicine
Graduate Assistant — Sept 1975-Jan 1976
Department of Pharmacology

Walter Reed Army Institute of Research

Founder & Chief, Neuropharmacology Branch (GM-16) — Sept 1981-Apr 1989
Research Pharmacologist (GS-14) — Sept 1976-Sept 1981
Department of Medical Neurosciences
Division of Neuropsychiatry

Walter Reed Army Institute of Research
Research Chemist (GM-12) — May 1972-Sept 1974
Chief Biochemist, Captain (MSC) — June 1969-Apr 1972
Departments of Psychiatry Microwave Research

University of Alabama
Graduate Assistant in Human Physiology — June 1967-Aug 1967
Graduate Laboratory Instructor in Zoology — Academic Years - 1966/67, 1967/68
Department of Biology

SELECTED HONORS AND ORGANIZATIONS

- **Fellow, American College of Neuropsychopharmacology** (1988)
- **Fellow, American College of Critical Care Medicine** (1992
- Member, Executive Committee, BIO 2003
- National Institute on Drug Abuse Public Advisory Committee (1988) **(Member)**
- U.S. Army Research and Development Achievement Award with Bronze Medallion (1984)
- International Advisory Board, Fondazione Giovanni Lorenzini Foundation, Pharmacological Basis of Anesthesiology (1982)
- U.S. Army Science Conference Award with Bronze Medallion for Outstanding Scientific Achievement (1980)
- U.S. Army Research and Development Achievement Award with Bronze Medallion (1980)
- University of Missouri Distinguished Visiting Scholar - School of Medicine, University of Missouri, Columbia, MO (Summer 1979)
- Dean N. Calvert Award for Scholarship and Research in Pharmacology (1977)
- Outstanding Graduate Research Award, University of California, San Francisco (1976)
- Department of Defense Training Fellowship (1974)

- Algernon Sydney Sullivan Award, Outstanding Alumnus, The University of Alabama (2008)

GRANT AND CONTRACT REVIEWS

- Department of the Army
- Medical Research Council (United Kingdom)
- National Institute for Drug Abuse ad hoc peer review (1980-1996)
- National Institute for Neurological Disorders and Stroke
- National Osteopathic Foundation
- National Science Foundation
- Veteran's Administration

GRADUATE STUDENTS, POST-DOCS AND FELLOWS

- Graduate Advisor and Committee Member for five Ph.D. Candidates
- Trained three post-doctoral students
- Trained six M.D. Fellows

EDITORIAL RESPONSIBILITIES

- Alcohol and Drug Research **(Editorial board until1990)**
- American Journal of Cardiology
- American Journal of Physiology
- Archives of Internal Medicine
- Brain Research
- Brain, Behavior, and Immunity
- Chest
- Circulation
- Circulatory Shock **(Associate Editor)**
- Clinical Pharmacology and Therapeutics
- Convulsive Therapy
- Critical Care Medicine **(Editorial board, 1985-1991), (Editorial board, 1993)**
- Drug Development Research **(Editorial board)**
- European Journal of Pharmacology
- Endocrinology
- Federation Proceedings
- Gene
- Heart and Lung: Journal of Critical Care
- Hypertension
- International Journal of Protein and Peptide Research
- Journal of Applied Physiology
- Journal of the American Medical Association
- Journal of Clinical Investigation
- Journal of Cancer Research
- Journal of Molecular and Cellular Cardiology
- Journal of Neuroscience
- Journal of Neuroscience Methods

- Journal of Neurotrauma **(Editorial board until 1994)**
- Journal of Pharmacology and Experimental Therapeutics
- Life Sciences **(Editorial board until 1992)**
- Medicine and Science in Sports and Exercise
- Nature
- Neuroendocrinology
- Neuropharmacology
- Pediatric Research
- Peptides **(Editorial board)**
- Pharmacology, Biochemistry and Behavior
- Physiology and Behavior
- Proceedings of the National Academy of Sciences
- Proceedings of the Society for Experimental Biology and Medicine
- Progress in NeuroEndocrinImmunology **(Editorial Board)**
- Psychiatry Research
- Psychoneuroendocrinology
- Regulatory Peptides
- Science
- Shock **(Founder, Editorial Board until 1996)**
- State-of-the-Art Series in Cellular Pathophysiology **(Editorial Board)**
- Trends in Pharmacological Sciences
- Trends in Shock Research **(Series Editor)**

SOCIETY MEMBERSHIPS

- American College of Neuropsychopharmacology **(Fellow)**
- Society of Critical Care Medicine **(Elected Fellow, 1992, Program Committee 1986-1987 & Lilly Fellowship Committee 1989)**
- American Association for the Advancement of Science
- American Association for Cancer Research
- American Paralysis Association **(Science Advisory Board, 1986-88)**
- American Society for Pharmacology and Experimental Therapeutics **(Travel Award Committee, IUPHAR, 1986, 1990)**
- American Society for Photobiology (1990-1995)
- International Narcotics Research Conference **(Executive Committee, 1987-1990; program chair, 1991)**
- National Association For Biomedical Research
- Neurotrauma Society
- New York Academy of Sciences
- Shock Society **(Treasurer 1984-1988; Program Chairman 1991; Secretary 1990; President 1992-1993)**
- Sigma Xi
- Society for Neuroscience (1972-1998)

THESIS AND DISSERTATION

1. Holaday, J.W. An ultracentrifugational analysis of the male-inducing hormone from the M5 strain of Volvox aureus. M.S. thesis, Department of Biology, University of Alabama, **1969**.

2. Holaday, J.W. The pituitary-adrenal axis and opiate action. Ph.D. dissertation, Department of Pharmacology, University of California, San Francisco, **1977**.

BOOKS

1. Holaday, J.W., Law, P.Y. and Herz, A. Progress in Opioid Research: Proceedings of the 17th International Narcotic Research Conference, National Institute on Drug Abuse Research Monograph Series #75 DHHS Pub. No. (ADM)87-1507. Washington DC. US Govt. Print. Off., **1986**.
2. Holaday, J.W., Bihari, D. Brain Failure; Series - Update in Intensive Care and Emergency Medicine. Springer-Verlag, Volume 9, **1989**.
3. Chernow, B., Holaday, J.W., Zaloga, G. and Zaritsky, A. - The Pharmacologic Approach to the Critically Ill Patient, Second Edition, Williams and Wilkins, Baltimore, MD, **1988**.
4. Neugebauer, E. and Holaday, J.W. - Handbook on Mediators and Mechanisms in Septic Shock, **1993**.

JOURNAL ARTICLES

1969-1976:

1. Denton, Tom E., Meshad, M., Holaday, J.W., and O'Kelley, J.C. (1969). Ca and Sr influence oncarbohydrate synthesis and composition in protosiphon. **Plant and Cell Physiology**, 10, 711-714.
2. Rose, R.M., Holaday, J.W., and Bernstein, I.S. (1971). Plasma testosterone, dominance rank, and aggressive behavior in male rhesus monkeys. **Nature**, 231, 366-368.
3. Rose, R.M., Kreuz, L.E., Holaday, J.W., Sulak, K.J., and Johnson, C.E. (1972). Diurnal variation of plasma testosterone and cortisol. **Journal of Endocrinology**, 54, 177-178.
4. Natelson, B.H., Holaday, J.W., Meyerhoff, J., and Stokes, E. (1975). Temporal changes in growth hormone, cortisol and glucose: relation to light onset and behavior. **American Journal of Physiology**, 229, 409-415.
5. Natelson, B.H., Krasnegor, N., and Holaday, J.W. (1976). Relations between behavioral arousal and plasma cortisol levels in monkeys performing repeated free-operant avoidance sessions. **Journal of Comparative and Physiological Psychology**, 90(10), 958-969.

1977:

6. Holaday, J.W., Martinez, H.M., and Natelson, B.H. (1977). Synchronized ultradian cortisol rhythms in monkeys: persistence during corticotropin infusion. **Science**, 198, 56.

7. Holaday, J.W., Meyerhoff, J.L., and Natelson, B.H. (1977). Cortisol secretion and clearance in the rhesus monkey. **Endocrinology**, 100, 1178-1185.
8. Holaday, J.W., Law, P.-Y., Tseng, L.F., Loh, H.H., and Li, C.H. (1977). β-endorphin: pituitary and adrenal glands modulate its action. **Proceedings of the National Academy of Sciences USA**, 74, 4628-4632.

1978:

9. Holaday, J.W., Loh, H.H., and Li, C.H. (1978). Unique behavioral effects of β-endorphin and their relationship to thermoregulation and hypothalamic function. **Life Sciences**, 22, 1525-1536.
10. Holaday, J.W., Tseng, L.F., Loh, H.H., and Li, C.H. (1978). Thyrotropin releasing hormone antagonizes β-endorphin hypothermia and catalepsy. **Life Sciences**, 22, 1537-1544.
11. Schmidt, W.K., Holaday, J.W., Loh, H.H., and Way, E.L. (1978). Failure of vasopressin and oxytocin to antagonize acute morphine antinociception or facilitate narcotic tolerance development. **Life Sciences**, 23, 151-158.
12. Holaday, J.W., Wei, E., Loh, H.H., and Li, C.H. (1978). Endorphins may function in heat adaptation. **Proc. Natl. Acad. Sci. USA**, 75, 2923-2927.
13. Holaday, J.W. and Faden, A.I. (1978). Naloxone reversal of endotoxin hypotension suggests role of endorphins in shock. **Nature**, 275, 450-451.
14. Holaday, J.W. and Natelson, B.H. (1978). Ultradian cortisol rhythms in monkeys: synchronized or not synchronized? **Science**, 202, 1001-1002.

1979:

15. Faden, A.I. and Holaday, J.W. (1979). Opiate antagonists: a role in the treatment of hypovolemic shock. **Science**, 205, 317-318.
16. Holaday, J.W., Dallman, M.F., and Loh, H.H. (1979). Effects of hypophysectomy and ACTH on opiate tolerance and physical dependence. **Life Sciences**, 24, 771-782.
17. Holaday, J.W., Law, P.-Y., Loh, H.H., and Li, C.H. (1979). Adrenal steroids indirectly modulate morphine and β-endorphin effects**. Journal of Pharmacology and Experimental Therapeutics**, 268, 176-184.
18. Belenky, G.L. and Holaday, J.W. (1979). The opiate antagonist naloxone modifies the effects of electroconvulsive shock (ECS) on respiration, blood pressure, and heart rate. **Brain Research**, 177, 414-417.
19. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1979). Naloxone alteration of physiologic parameters in spinally transected animals. **Transactions of the American Neurological Association**, 104, 1-5.

1980:

20. Faden, A.I. and Holaday, J.W. (1980). Naloxone treatment of endotoxin shock: stereospecificity of physiologic and pharmacologic effects in the rat. **Journal of Pharmacology and Experimental Therapeutics**, 212, 441-447.
21. Reynolds, D.G., Gurll, N.J., Vargish, T., Lechner, R., Faden, A.I., and Holaday, J.W. (1980). Blockade of opiate receptors with naloxone improves survival and cardiac performance in canine endotoxic shock. **Circulatory Shock**, 7, 39-48.

22. Vargish, T., Reynolds, D.G., Gurll, N.J., Lechner, R.J., Holaday, J.W., and Faden, A.I. (1980). Naloxone reversal of hypovolemic shock in dogs. **Circulatory Shock**, 7, 31-38.
23. Holaday, J.W. and Faden, A.I. (1980). Naloxone acts at central opiate receptors to reverse hypotension, hypothermia, and hypoventilation in spinal shock. **Brain Research**, 189, 295-299.
24. Faden, A.I. and Holaday, J.W. (1980). Experimental endotoxin shock: the pathophysiologic function of endorphins and treatment with opiate antagonists. **Journal of Infectious Diseases**, 142, 229-238.
25. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1980). Endorphin-parasympathetic interaction in spinal shock. **J. Autonomic Nervous System**, 2, 295-304.
26. Holaday, J.W. and Belenky, G.L. (1980). Opiate-like effects of electroconvulsive shock in rats: a differential effect of naloxone on nociceptive measures. **Life Sciences**, 27, 1929-1938.

1981:

27. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1981). Opiate antagonist improves neurologic recovery after spinal injury. **Science**, 211, 493-494.
28. Holaday, J.W., O'Hara, M., and Faden, A.I. (1981). Hypophysectomy alters cardiorespiratory variables: central effects of pituitary endorphins in shock. **American Journal of Physiology**, 241 (Heart & Circ. Physiol 10), H479-H495.
29. Belenky, G.L. and Holaday, J.W. (1981). Repeated electroconvulsive shock (ECS) and morphine tolerance: demonstration of cross sensitization in the rat. **Life Sciences**, 29, 553-563.
30. Faden, A.I., Jacobs, T.P., Feuerstein, G., and Holaday, J.W. (1981). Dopamine partially mediates the cardiovascular effects of naloxone after spinal injury. **Brain Research**, 213, 415-421.
31. Faden, A.I., Jacobs, T.P., Mougey, E.H., and Holaday, J.W. (1981). Endorphins in experimental spinal injury: therapeutic effect of naloxone. **Annals of Neurology**, 10, 326-332.
32. Holaday, J.W. and Faden, A.I. (1981). Endorphins in shock and spinal injury: therapeutic role for opiate antagonists. **Psychopharmacology**, 17, 74-76.
33. Holaday, J.W. and Faden, A.I. (1981). The pathophysiologic role of endorphins in experimental shock. **Journal of Infectious Diseases**, 143, 863-864.
34. Holaday, J.W., D'Amato, R.J., and Faden, A.I. (1981). Thyrotropin releasing hormone improves cardiovascular function in experimental endotoxic and hemorrhagic shock. **Science**, 213, 216-218.
35. Holaday, J.W., Ruvio, B.A., and Faden, A.I. (1981). Thyrotropin releasing hormone improves blood pressure and survival in endotoxic shock. **European Journal of Pharmacology**, 74, 101-105.
36. Holaday, J.W. and Faden, A.I. (1981). Naloxone treatment in shock. **Lancet,** 1, 201.
37. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1981). Thyrotropin releasing hormone improves neurological recovery after spinal trauma in cats. **New England Journal of Medicine**, 305, 1063-1067.
38. Tortella, F.C., Cowan, A., Belenky, G.L. and Holaday, J.W. (1981). Opiate-like electroencephalographic and behavioral effects of electroconvulsive shock in rats. **European Journal of Pharmacology**, 76, 121-128.

1982:

39. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1982). Thyrotropin releasing hormone for spinal trauma (letter: Hall, E.D. and Braughler, J.M.). **New England Journal of Medicine**, 306, 429-430.
40. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1982). Comparison of early and late naloxone treatment in experimental spinal injury. **Neurology**, 32, 677-681.
41. Holaday, J.W. and D'Amato, R.J. (1982). Naloxone or TRH fails to improve neurologic deficits in gerbil models of "stroke". **Life Sciences**, 31, 385-392.
42. Holaday, J.W. and D'Amato, R.J. (1982). Naloxone in Cerebral Ischaemia. **Lancet**, May 29, 1238.
43. Holaday, J.W., Ruvio, B.A., Robles, L.E., Johnson, C.E., and D'Amato, R.J. (1982). ICI M154,129, a putative δ antagonist, reverses endotoxic shock without altering morphine analgesia. **Life Sciences**, 31, 2209-2212.
44. Holaday, J.W., Hitzemann, R.J., Curell, J., Tortella, F.C., and Belenky, G.L. (1982). Repeated electroconvulsive shock or chronic morphine treatment increases the number of ^{3}H-D-Ala^{2}, D-Leu^{5}-enkephalin binding sites in rat brain membranes. **Life Sciences**, 31, 2359-2362.
45. Holaday, J.W. and D'Amato, R.J. (1982). Naloxone and ischemic neurologic deficits in the gerbil: is there an effect? **Science**, 218, 592-593.
46. Holaday, J.W. (1982). Cardiorespiratory effects of μ and δ opiate agonists following 3rd or 4th ventricular injections. **Peptides**, 3, 1023-1029.
47. Faden, A. I., Jacobs, T. P., & Holaday, J. W. (1982). Neuropeptides and spinal cord injury. *Advances in biochemical psychopharmacology*, *33*, 131–8.

1983:

47. Holaday, J.W. (1983). Cardiovascular consequences of endogenous opiate antagonism. Invited commentary, **Biochemical Pharmacology**, Pergamon Press, New York, 573-585.
48. Faden, A.I., Jacobs, T.P., Smith, M.T., and Holaday, J.W. (1983). Comparison of Thyrotropin Releasing Hormone (TRH), Naloxone, and Dexamethasone Treatments in Experimental Spinal Injury. **Neurology**, 33, 673-678.
49. Holaday, J.W., Pasternak, G.W., and Faden, A.I. (1983). Naloxazone pretreatment modifies cardiorespiratory and behavioral effects of morphine. **Neuroscience Letters**, 37, 199-204.
50. Holaday, J.W., Pasternak, G.W., D'Amato, R.J., Ruvio, B.A., and Faden, A.I. (1983). Naloxazone lacks therapeutic effects in endotoxic shock yet blocks the effects of naloxone. **European Journal of Pharmacology**, 89, 293-296.
51. Belenky, G.L., Gelinas-Sorell, D., Kenner, J.R., and Holaday, J.W. (1983). Evidence for δ receptor involvement in the post-ictal antinociceptive responses to electroconvulsive shock in rats. **Life Sciences**, 33, 585-586.
52. Tortella, F.C., Robles, L.E., Holaday, J.W., and Cowan, A. (1983). A selective role for δ-receptors in the regulation of opioid-induced changes in seizure threshold. **Life Sciences**, 33, 603-606.
53. Holaday, J.W., and D'Amato, R.J. (1983). Multiple opioid receptors: evidence for μ-δ binding site interactions in endotoxic shock. **Life Sciences**, 33, 703-706.

54. Holaday, J.W., D'Amato, R.J., Ruvio, B.A., Feuerstein, G., and Faden, A.I. (1983). Adrenalectomy blocks pressor responses to naloxone in endotoxic shock: evidence for sympatho-medullary involvement. **Circulatory Shock**, 11, 201-210.
55. Holaday, J.W., and Faden, A.I. (1983). TRH: Autonomic effects upon cardiorespiratory function in endotoxic shock. **Regulatory Peptides**, 7, 111-125.

1984:

56. Holaday, J.W. (1984). Opiate antagonists in shock and trauma. **American Journal of Emergency Medicine**, 2, 8-12.
57. Tortella, F.C., Cowan, A. and Holaday, J.W. (1984). Pituitary opioid involvement in electroconvulsive shock-induced postictal electrogenesis and behavioral depression in rats. **Peptides**, 5, 115-118.
58. D'Amato, R.J., and Holaday, J.W. (1984). Multiple opiate receptors in endotoxic shock: evidence for δ involvement and μ-δ interactions in vivo. **Proc. Natl. Acad. Sci. USA**, 81, 2898-2901.
59. Holaday, J.W., and Bernton, E.W. (1984). Thyrotropin releasing hormone: a potent neuromodulator with therapeutic potential. **Archives of Internal Medicine**, 144, 1138-1140.
60. Tortella, F.C., Robles, L.E., Holaday, J.W. and Cowan, A. (1984). 1C1 154, 129, a δ opioid receptor antagonist raises seizure threshold in rats. **European Journal of Pharmacology**, 97, 141-144.
61. Tortella, F.C., and Holaday, J.W. (1984). μ and δ opioid receptor interactions in a rat model of drug induced seizures. **Proc. West. Pharmacol. Society**, 27, 435-437.
62. Holaday, J.W., Kenner, J.R., Glatt, C.E. & Long, J.B. (1984). Dynorphin: Cardiovascular consequences of opioid receptor interactions in normal and endotoxemic rats. **Proc. West. Pharmacol. Society**, 27, 429-433.
63. Holaday, J.W. (1984). Internal and external opioids update. **U.S. Journal of Drug and Alcohol Dependence**, 8, 19.
64. Tapp, W.N., Holaday, J.W. & Natelson, B.H. (1984). Ultradian glucocorticoid rhythms in monkeys and rats continue during stress. **American Journal of Physiology**, 866-871.
65. Tortella, F.C., Robles, L., Mosberg, H.I. and Holaday, J.W. (1984). Electroencephalographic assessment of the role of δ receptors in opioid peptide-induced seizures. **Neuropeptides**, 5, 213.
66. Long, J.B., Ruvio, B.A., Glatt, C.E. and Holaday, J.W. (1984). ICI 174864, a putative δ opioid antagonist, reverses endotoxemic hypotension: pretreatment with dynorphin 1-13, a κ agonist, blocks this action. **Neuropeptides**, 5, 291-294.
67. Chernow, B. and Holaday, J.W. (1984). The pathogenesis of septic shock. **J.A.M.A. Letter**, 252, 20B.
68. Tortella, F.C., Robles, L, Holaday, J.W., and Cowan, A. (1984). ICI 154,129, a δ opiate receptor antagonist raises seizure threshold in rats. **European Journal of Pharmacology**, 97, 141-144.
69. Sampson, J.A., Bass, B.L., Harmon, J.W., and Holaday, J.W. (1984). Naloxone reduces renal blood flow in rabbit hemorrhagic shock. **Surgical Forum**.
70. Dixon, W.R., Viveros, O.H., Unsworth, C.D., Diliberto, E.J., Jr., Way, E.L., Lewis, J.W., Chandra, A., Holaday, J.W., Long, J.B., and Tortella, F.C. (1984). Multiple opiate receptors: functional implications. **American Society for Pharmacology and Experimental Therapeutics**, December 7.

1985:

71. Long, J.B. and Holaday, J.W. (1985). Blood-brain barrier: endogenous modulation by adrenal-cortical function. **Science**, 227, 1580-82.
72. Bernton, E.W., Long, J.B. & Holaday, J.W. (1985). Opioids and neuropeptides: mechanisms in circulatory shock. **Federation Proceedings**, 44, 290-299.
73. Tortella, F.C., Long, J.B., and Holaday, J.W. (1985). Endogenous opioid systems: physiological role in the self-limitation of seizures. **Brain Research**, 332, 174-178.
74. Tortella, F.C., Robles, L. and Holaday, J.W. (1985). The anticonvulsant effects of DADLE are primarily mediated by activation of δ opioid receptors: Interactions between δ and μ receptor antagonists. **Life Sciences**, 37, 497-503.
75. Malcolm, D.S. and Holaday, J.W. (1985). Opioid peptides and their antagonists: a role in respiratory function. **Seminars in Respiratory Medicine**, 7, 81-87.
76. Gilbeau, P.M., Almirez, R.G., Holaday, J.W,. and Smith, C.G. (1985). The role of endogenous opioids peptides in the control of androgen levels in the male non-human primate. **Journal of Andrology**, 5, 339-343.
77. Gilbeau, P.M., Almirez, R.G., Holaday, J.W. and Smith, C.G. (1985). Opioid effects on plasma concentrations of luteinizing hormone and prolactin in the adult male rhesus monkey. **Journal of Clinical Endocrinology and Metabolism**, 60, 299-305.
78. Holaday, J.W., Long, J.B. and Tortella, F.C. (1985). Evidence for κ, μ and δ opioid binding site interactions in vivo. **Federation Proceedings**, 44, 2860-2862.
79. Kinney, R.C., Holaday, J.W., Harmon, J.W. (1985). Naloxone decreases neurologic deficits in experimental aortic cross-clamping ischemia. **Surgical Forum**, 36, 460-461.
80. Gruenke L D; Craig J C; Klein F D; Nguyen T L; Hitzemann B A; Holaday J W; Loh H H; Braff L; Fischer A; Glick I D. (1985). Determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry: application to biological fluids. **Biomedical mass spectrometry**, 12, (12) 707-13.
81. Dixon W R; Viveros O H; Unsworth C D; Diliberto E J; Way E L; Lewis J W; Chandra A; Holaday J W; Long J B; Tortella F C. (1985). Multiple opiate receptors: functional implications. **Federation proceedings**, 44, (13) 2851-62.

1986:

82. Long, J.B., Lake, C. R., Reid, A.A., and Holaday, J.W. (1986). Effects of naloxone and thyrotropin releasing hormone on plasma catecholamines, corticosterone, and arterial pressure in normal and endotoxemic rats. **Circulatory Shock**, 18, 1-10.
83. Tortella, F.C., Robles, L. and Holaday, J.W. (1986). U50,488, a highly selective kappa opioid: anticonvulsant profile in rats. **Journal of Pharmacology and Experimental Therapeutics**, 237(1), 49-53.
84. Malcolm, D., Zaloga, G.P., Chernow, B. and Holaday, J.W. (1986). Glucagon is an antagonist of morphine bradycardia and antinociception. **Life Sciences**, 39, 399-405.
85. Rothman, R.B., Danks, J.A., Jacobson, A.E., Burke, T.R., Rice, K.C., Tortella, F.C. and Holaday, J.W. (1986). Morphine tolerance increases μ noncompetitive δ binding sites. **European Journal of Pharmacology**, 124, 113-119.
86. Chernow, B., Reed, L., Geelhoed, G.D., Anderson, M., Teich, S., Meyerhoff, J., Beardsley, D., Lake, C.R. and Holaday, J.W. (1986). Glucagon: endocrine effects and calcium involvement in cardiovascular actions in dogs. **Circulatory Shock**, 19, 393-407.

87. Long, J.B., Martinez-Arizala, A., Petras, J.M. and Holaday, J.W. (1986). Endogenous opioids in spinal cord injury: a critical evaluation. **Central Nervous System Trauma**, 3(4), 295.
88. Kinney, R.C., Long, J.B., Malcolm, D.S., Holaday, J.W. and Graeber, G. (1986). Intrathecal injection of the opiate peptide dynorphin reduces spinal cord blood flow. **Surgical Forum**, 27, 485-486.

1987:

89. Zaloga, G.P., Malcolm, D.S., Holaday, J.W. and Chernow B. (1987). Verapamil reverses calcium cardiotoxicity. **Annals of Emergency Medicine**, 16(6), 637-639.
90. Gurll, N.J., Holaday, J.W., Reynolds, D.G. and Ganes, E. (1987). Thyrotropin releasing hormone: characterization of its effects in monkeys and dogs subjected to experimental circulatory shock. **Critical Care Medicine**, 15(6), 574-581.
91. Chernow, B., Zaloga, G.P., Malcolm, D.S., Willey, S.C., Clapper, M. and Holaday, J.W. (1987). Glucagon's chronotropic action is calcium dependent. **Journal of Pharmacology and Experimental Therapeutics**, 241(3), 833-837.
92. Hitzemann, R.J., Hitzemann, B., Blatt, S., Tortella, F.C., Kenner, J., Belenky, G.L. and Holaday, J.W. (1987). Repeated electroconvulsive shock: effect on sodium dependency and regional distribution of opioid-binding sites. **Molecular Pharmacology**, 31(5), 562.
93. Bryant, H.U., Bernton E.W. and Holaday, J.W. (1987). Immunosuppressive effects of chronic morphine treatment in mice. **Life Sciences**, 41, 1731-1738.
94. Bernton, E.W., Beach, J.E., Holaday, J.W., Smallridge, R.C. and Fein, H.G. (1987). Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. **Science**, 238, 519-521.
95. Long, J.B., Kinney, R.C., Malcolm, D.S., Graeber, G.M. and Holaday, J.W. (1987). Intrathecal dynorphin A (1-13) and dynorphin A (3-13) reduce rat spinal cord blood flow by non-opioid mechanisms. **Brain Research**, 436, 374-379.
96. Glatt, C.E., Kenner, J.R., Long, J.B. and Holaday, J.W. (1987). Cardiovascular effects of dynorphin A (1-13) in conscious rats and its modulation of morphine bradycardia over time. **Peptides**, 8, 1089-1092.
97. Rothman, R.B., McLean, S., Bykov, V., Lessor, R.A., Jacobson, A.E., Rice, K.C. and Holaday, J.W. (1987). Chronic morphine upregulates an opiate binding site labeled by [3H]cycloFOXY: a novel opiate antagonist suitable for positron emission tomography. **European Journal of Pharmacology**, 142, 73-81.

1988:

98. Rothman, R.B., Long, J.B., Bykov, V., Jacobsen, A.E., Rice, K.C. and Holaday, J.W. (1988). β-FNA binds irreversibly to the opiate receptor complex: in vivo and in vitro evidence. **Journal of Pharmacology and Experimental Therapeutics**, 247, 405-416.
99. Bernton, E.W., Meltzer, M.S., and Holaday, J.W. (1988). Suppression of macrophage activation and T-lymphocyte function in hypoprolactinemic mice. **Science**, 239, 401-404.
100. Long, J.B., Petras, J.M. and Holaday, J.W. (1988). Neurological deficits and neuronal injury in rats resulting from non-opioid actions of the delta opioid receptor antagonist

ICI 174864. **Journal of Pharmacology and Experimental Therapeutics**, 244, 1169-1177.

101. Gurll, N.J., Reynolds, D.G. and Holaday, J.W. (1988). Evidence for a role of endorphins in the cardiovascular pathophysiology of primate shock. **Critical Care Medicine**, 16(5), 521-530.
102. Bryant, H.U., Yoburn, B.C., Inturrisi, C.E., Bernton, E.W. and Holaday, J.W. (1988). Morphine-induced immunomodulation is not related to serum morphine concentrations. **European Journal of Pharmacology**, 149, 165-169.
103. Zaloga, G.P., Malcolm, D., Chernow, B. and Holaday, J.W. (1988). Endotoxin-induced hypocalcemia results in defective calcium mobilization in rats. **Circulatory Shock**, 24(2), 143-148.
104. Bryant, H.U., Bernton, E.W. and Holaday, J.W. (1988). Morphine pellet-induced immunomodulation in mice: temporal relationships. **Journal of Pharmacology and Experimental Therapeutics**, 245(3), 913-920.
105. Hinshaw, L.B., Archer, L.T., Beller, B.K., Ishida, K., Chang, A.C., Brackett, D.J., Flourney, D.J., Passey, R.B., Wilson, M.F., Long, J.B. and Holaday, J.W. (1988). Evaluation of naloxone therapy for E. coli sepsis in the baboon. **Archive of Surgery**, 123(6), 700-704.
106. Long, J.B., Martinez-Arizala, A., Echevarria, E.E., Tidwell, R.E., and Holaday, J.W. (1988). Hindlimb paralytic effects of prodynorphin-derived peptides following spinal subarachnoid injection in rats. **European Journal of Pharmacology**, 153, 45-54.
107. Danks, J.A., Tortella, F.C., Long, J.B., Bykov, V., Jacobsen, A.E., Rice, K.C., Holaday, J.W. and Rothman, R.B. (1988). Chronic administration of morphine and naltrexone upregulate [^{3}H]-[D-Ala^2,D-Leu^5] enkephalin binding sites by different mechanisms. **Neuropharmacology**, 27(9), 965-974.
108. Long, J.B., Mobley, W.C. and Holaday, J.W. (1988). Neurological dysfunction following intrathecal injection of dynorphin A (1-13) in the rat. I: Injection procedures modify pharmacological responses. **Journal of Pharmacology and Experimental Therapeutics**, 246(3), 1158-1166.
109. Malcolm, D.S., Zaloga, G.P., Willey, S.C. and Holaday, J.W. (1988). Naloxone potentiates epinephrine's hypertensive effects in endotoxemic rats. **Circulatory Shock**, 25, 259-265.
110. Martinez-Arizala, A., Long, J.B. and Holaday, J.W. (1988). TRH fails to antagonize the acute paralytic effects of intrathecal dynorphin A and substance P antagonists in the rat. **Brain Research**, 473, 385-388.
111. Long, J.B, Petras, J.M., Mobley, W.C. and Holaday, J.W. (1988). Neurological dysfunction following intrathecal injection of dynorphin A (1-13) in the rat. II: Non-opioid mechanisms mediate loss of motor, sensory, and autonomic function. **Journal of Pharmacology and Experimental Therapeutics**, 246, 1167-1171.
112. Zaloga, G.P., Willey, S., Malcolm, D.S., Chernow, B. and Holaday, J.W. (1988). Hypercalcemia attenuates blood pressure response to epinephrine. **Journal of Pharmacology and Experimental Therapeutics**, 247, 949-952.
113. Tortella, F.C., Robles, L., Mosberg, H.I. and Holaday, J.W. (1988). Anticonvulsant effects of mu (DAGO) and delta (DPDPE) enkephalins in rats. **Peptides**, 9, 1177-1181.
114. Holaday, J.W. Bryant, H.U., Kenner, J.R. and Bernton, E.W. (1988). Pharmacologic manipulation of the endocrine-immune axis. **Progress in NeuroEndocrinImmunology (PNEI Perspectives)**, 1(3), 6-8.
115. Rhee, H.M., Holaday, J.W., Long, J.B., Guamann, M.D., Yaksh, T.L., Tyce, G.M., Dixon, W.R., Chang, A.P., Mastrianni, J.A., Mosequeda-Garcia, R. and Kunos, G.

(1988). Do opioid receptors play a role in blood pressure regulation? **The Korean Journal of Pharmacology**, 24(2).

116. Zaloga, G.P., Willey, S.C., Malcolm, D.S., Chernow, B. and Holaday, J.W. (1988). Hypercalcemia attenuates epinephrine's hypertensive effect. **Journal of Pharmacology and Experimental Therapeutics**, 247, 949-952.

1989:

117. Beach, J.E., Smallridge, R.C., Kinzer, C.A., Bernton, E.W., Holaday, J.W. and Fein, H.G. (1989). Rapid release of multiple hormones from rat pituitaries perifused with recombinant interleukin-1. **Life Sciences**, 44, 1-7.
118. Martinez-Arizala, A., Holaday, J.W. and Long, J.B. (1989). Cardiovascular responses to intrathecal vasopressin in conscious and anesthetized rats. **American Journal of Physiology**, 256, R193-R200.
119. Tortella, F.C., Echevarria, E., Lipkowski, A.W., Takemori, A.E., Portoghese, P. and Holaday, J.W. (1989). Selective kappa antagonist properties of nor-binaltorphimine in the rat MES seizure model. **Life Sciences**, 44, 661-665.
120. Schaefer, C.F., Brackett, D.J., Biber, B., Lerner, M.R., Holaday, J.W., Wilson, M.F. and Fagraeus, L. (1989). Respiratory and cardiovascular effects of thyrotropin releasing hormone as modified by isoflurane, enflurane, pentobarbital and ketamine. **Regulatory Peptides**, 24, 269-282.
121. Holaday, J.W., Long, J.B., Martinez-Arizala, A., Chen, H-S., Reynolds, D.G. and Gurll, N.J. (1989). Effects of TRH in circulatory shock and central nervous system ischemia. Reprinted from Thyrotropin-Releasing Hormone: Biomedical Significance, **Annals of the New York Academy of Science**, 553.
122. Cuthbert, B.N., Holaday, J.W., Meyerhoff, J. and Choh, H.L. (1989). Intravenous beta-endorphin: behavioral and physiological effects in conscious monkeys. **Peptides**, 10, 729-734.
123. Martinez-Arizala, A. and Holaday, J.W. (1989). Is there a role for naloxone in the treatment of stroke? **Critical Care Medicine**, 17(8), 839-840.
124. Hartmann, D.P., Holaday, J.W. and Bernton, E.W. (1989). Inhibition of lymphocyte proliferation by antibodies to prolactin. **The FASEB Journal**, 3, 2194-2202.
125. Long, J.B., Martinez-Arizala, A., Rigamonti, D.D. and Holaday, J.W. (1989). Hindlimb paralytic effects of arginine vasopressin and related peptides following spinal subarachnoid injection in the rat. Peptides, 9, 1335-1344.
126. Holaday, J.W., Porreca F. and Rothman, R. (1989). Opioid receptor types. **Trends in Pharmaceutical Sciences**, 10(2).
127. Malcolm, D.S., Zaloga, G.P. and Holaday, J.W. (1989). Calcium administration increases the mortality of endotoxic shock in rats. **Critical Care Medicine**, 17, 900-903.
128. Reynolds, D.G., Gurll, N.J., Holaday, J.W. and Lechner, R.B. (1989). The therapeutic efficacy of opiate antagonists in hemorrhagic shock. **Resuscitation**, 18, 243-251.
129. Bryant, H.U., Holaday, J.W. and Bernton, E.W. (1989). Cysteamine produces dose-related bidirectional immunomodulatory effects in mice. **Journal of Pharmacology and Experimental Therapeutics**, 249, 424-429.

130. Rothman, R.B., Bykov, V., Long, J.B., Brady, L.S., Jacobson, A.E., Rice, K.C. and Holaday, J.W. (1989). Chronic administration of morphine and naltrexone up-regulate μ–opioid binding sites labeled by [^{3}H][D-Ala^2,MePhe^4, Gly-ol^5]enkephalin: further evidence for two μ-binding sites. **European Journal of Pharmacology**, 160, 71-82.
131. Tortella, F.C., Echevarria, E., Holaday, J.W., Kazmierski, W., Hruby, V.J., Burks, T.F. and Shook, J.E. (1989). Opioid antagonist properties of CTP, a somatostatin analog: in vivo selectivity for μ–directed ligands. **Adv. Biosciences**, 75, 387-390.
132. Long J B; Martinez-Arizala A; Johnson S H; Holaday J W. (1989). Arginine8-vasopressin reduces spinal cord blood flow after spinal subarachnoid injection in rats. **The Journal of pharmacology and experimental therapeutics**, 249, (2): 499-506.
133. Rothman, R. B., Long, J. B., Holaday, J. W., Bykov, V., de Costa, B. R., Kim, C. H., Jacobson, A. E., et al. (1989). A study of the interaction of the alkylating agent, NIH10236, with opioid receptors in vitro and in vivo. *Neuropharmacology*, *28*(12), 1349–56.

1990:

134. Brackett, D.J., Schaefer, C.F., Lerner, M.R., Holaday, J.W., Fagraeus, L., and Wilson, M.F. (1990). Evaluation of thyrotropin releasing hormone as a therapeutic intervention for endotoxemia. **Regulatory Peptides**, 29, 153-162.
135. Rothman, R.B., Long, J.B., Bykov, V., Jacobson, A.E., Rice, K.C. and Holaday, J.W. (1990). Pretreatment of rats with the irreversible μ-receptor antagonist, β-FNA, fails to prevent naltrexone-induced upregulation of μ-opioid receptors. **Neuropharmacology**, 29, 805-810.
136. Tortella, F. C., Long, J. B., Hong, J.-S., & Holaday, J. W. (1989). Modulation of Endogenous Opioid Systems by Electroconvulsive Shock. *Convulsive therapy*, *5*(3), 261–273.
137. Rothman, R.B., Long, J.B., Holaday, J.W., Bykov, V., de Costa, B.R., Chong-Ho, K., Jacobson, A.E. and Rice, K.C. (1990). A study of the interaction of the alkylating agent NIH10236 with opioid receptors in vitro and in vivo. **Neuropharmacology**, 28, 1349-1356.
138. Martinez-Arizala, A., Rigamonti, D.D., Long, J.B., Kraimer, J.M. and Holaday, J.W. (1990). Effects of NMDA receptor antagonists following spinal ischemia in the rabbit. **Experimental Neurology**, 108, 232-240.
139. Kenner, J.R., Holaday, J.W., Bernton, E.W. and Smith, P.F. (1990). Prolactin-like protein in murine splenocytes: morphological and biochemical evidence. Progress in **NeuroEndocrinImmunology**, 188-195.

1991:

140. Bryant, H.U., Bernton, E.W., Kenner, J.R., and Holaday, J.W. (1991). Role of adrenal cortical activation in the immunosuppressive effects of chronic morphine treatment. **Endocrinology**, 128, 3253-3258.
141. Rothman, R.B., Long, J.B., Bykov, V., Xu, Heng, Jacobson, A.E., Rice, K.C., and Holaday, J.W. (1991). Upregulation of the opioid receptor complex by the chronic administration of morphine: a biochemical marker related to the development of tolerance and dependence. **Peptides**, 12, 151-160.

142. Rothman, R.B., Bykov, V., Mahboubi, A., Long, J.B., Jiang, Q., Porreca, F., DeCosta, B.R., Jacobson, A.E., Rice, K.C., & Holaday, J.W. (1991). Interaction of β-

funaltrexamine with [^{3}H] cycloFOXY binding in rat brain: further evidence that β-FNA alkylates the opioid receptor complex. **Synapse**, 8, 86-99.

1992:

143. Bernton, E., Bryant, H., Holaday, J.W., and Dave, J. (1992). Prolactin and prolactin secretagogues reverse immunosuppression in mice treated with cysteamine, glucocorticoids, or cyclosporin-A. **Brain, Behavior, and Immunity**, 6, 394-408.
144. Holaday, John W. (1992). Neuroendocrine immunology: relevance to the management of critical illness. **Critical Care Medicine**, 20, 1631-1633.

1993:

145. Dosaka-Akita, K., Tortella, F.C., Holaday, J.W., and Long, J.B. (1993). The kappa opioid agonist U-50, 488H antagonizes respiratory effects of mu opioid receptor agonists in conscious rats. **The Journal of Pharmacology and Experimental Therapeutics**, 264(2), 631-637.

1994:

146. Compton, C., Rizk, I., Regauer, S., Kenner, J., Holaday, J., and Burd, E. (1994) The Effect of Bromocryptine-Induced Hypoprolactinemia on Xenogeneic and Allogeneic Skin Graft Survival in a Mouse Model. **The Journal of Burn Care and Rehabilitation**, September/October 1994, 393-399.

1999

147. Fortier, Anne H., Nelson, Barbara J., Grella, Davida K., Holaday, John W. (1999) Antiangiogenic Activity of Prostate-Specific Antigen **Journal of the National Cancer Institute**, 1635-1640, Vol. 91, No. 19, October 6, 1999.

2000

148. Fortier, A.H., Grella, D.K., Nelson, B.J. and Holaday, J.W. Response to "Angiogenic Activity of Prostate-Specific Antigen." **Journal of the National Cancer Institute**. Vol. 92, No. 4, pages 345-346, February 2000.

149. Plum, Stacy M., Holaday, John W., Ruiz, A., Madsen, John W., Fogler, William E., Fortier, Anne H. (2000) Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. **Vaccine** 19 (2000) 1294-1303.

2002

150. Lin-Hong Li, Rama Shivakumar, Stephanie Feller, Cornell Allen, Jonathan M. Weiss, Sergey Dzekunov, Vin Singh, **John Holaday**, Joseph Fratantoni, Linda N. Liu (2002) "Highly Efficient, Large Volume Flow Electroporation" **Tech. in Cancer Research and Treatment** 1 (5): 341-349.

151. Holaday, JW, Meltzer, SL, and McCormick, JT "Strategies for attracting angel investors" **Journal of Commercial Biotechnology** 12/2002; 9(2):129-133

2003- Present

152. Fortier A H; Holaday J W; Liang H; Dey C; Grella D K; Holland-Linn J; Vu H; Plum S M; Nelson B J. (2003) "Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo." **The Prostate** 56 (3): 212-9.

153. J. W. Holaday, P. Richards (2009) "Dual-Opioids™ (morphine+oxycodon) provide analgesia with reduced side effects in acute surgical pain" **Perioperative Medizin** 12; 1(4):244-244

154. Holaday, JW, Berkowitz, BA (2009) Antiangiogenic Drugs: Insights into drug development from Endostatin, Avastin and Thalidomide. **Molecular Interventions** 09/2009; 9(4):157-66.

BOOK CHAPTERS

1978:

1. Loh, H.H., Tseng, L.F., Holaday, J.W., and Wei, E. (1978). Endogenous peptides and opiate action. In M. Adler (Ed.), Factors Affecting the Action of Narcotics (pp. 387-402). New York: Raven Press.

1979:

2. Holaday, J.W. and Loh, H.H. (1979). Endorphin-opiate interactions with neuroendocrine systems. In H.H. Loh and D.H. Ross (Eds.), Neurochemical Mechanisms of Opiates and Endorphins (pp. 227-258). New York: Raven Press.
3. Holaday, J.W., Loh, H.H., Wei, E., and Li, C.H. (1979). Possible role of β-endorphin in heat adaptation. In E. Usdin (Ed.), Endorphins in Mental Health Research (pp. 463-483). London: The Macmillan Press.
4. Holaday, J.W., Belenky, G.L., Faden, A.I., and Loh, H.H. (1979). Possible function of β-endorphin. In B. Saletu et al (Eds.), Neuro-Psychopharmacology, (pp. 503-514). Oxford: Pergamon Press.
5. Belenky, G.L. and Holaday, J.W. (1979). Electroconvulsive shock (ECS) in rats: naloxone modification of post-ECS behaviors provides evidence for functional endorphin release. In E.L. Way (Ed.), Endogenous and Exogenous Opiate Agonists and Antagonists (pp. 487-490). New York: Pergamon Press.
6. Holaday, J.W. and Faden, A.I. (1979). Naloxone improvement of shock pathophysiology: evidence for opiate receptor involvement. In E.L. Way (Ed.), Endogenous and Exogenous Opiate Agonists and Antagonists (pp. 479-482). New York: Pergamon Press.

7. Faden, A.I. and Holaday, J.W. (1979). Naloxone reversal of hypotension caused by spinal transection. In E.L. Way (Ed.), Endogenous and Exogenous Opiate Agonists and Antagonists (pp. 483-486). New York: Pergamon Press.

1980:

8. Holaday, J.W. and Faden, A.I. (1980). The role of endorphins in the pathophysiology of shock and the therapeutic benefit of opiate antagonists. Army Science Conference Proceedings 2, 233-246.
9. Craig, J.C., Gruenke, L.D., Hitzemann, B.A., Holaday, J.W., and Loh, H.H. (1980). Simultaneous determination of chlorpromazine and its major metabolites in plasma and red blood cells by a GC/MS method: clinical implications. In Usdin, Eckert, and Forest.(Eds.), Phenothiazines and Structurally Related Drugs (pp. 129-132). Amsterdam: Elsevier/North Holland Biomedical Press.

1981:

10. Holaday, J.W. and Faden, A.I. (1981). Naloxone reverses the pathophysiology of shock through an antagonism of endorphin systems. In J. Martin, S. Reichlin, and K. Bick (Eds.), Neurosecretion and Brain Peptides: Implications for Brain Function and Neurological Disease (pp. 421-434). New York: Raven Press.
11. Faden, A.I. and Holaday, J.W. (1981). A role for endorphins in the pathophysiology of spinal cord injury. In J. Martin, S. Reichlin, and K. Bick (Eds.), Neurosecretion and Brain Peptides: Implications for Brain Function and Neurological Disease (pp. 435-446). New York: Raven Press.
12. Holaday, J.W. and Faden, A.I. (1981). Endorphin involvement in the pathophysiology of shock and trauma: therapeutic effects of naloxone. In A.G.B. Kovach et al (Eds.), Homeostasis of Injury and Shock (pp. 131-141). Akademiai Kaido, Budapest: Pergamon Press.
13. Holaday, J.W. and Loh, H.H. (1981). The neurobiology of β-endorphin and related peptides. In C.H. Li (Ed.), Hormonal Proteins and Peptides: β-Endorphin (pp. 202-291). New York: Academic Press.
14. Faden, A.I. and Holaday, J.W. (1981). Endorphins in traumatic spinal injury: pathophysiologic studies and clinical implications. In H. Emrich (Ed.), The Role of Endorphins in Neuropsychiatry (pp. 158-174). Basel, Switzerland: S. Karger.
15. Holaday, J.W., Tortella, F.C., and Belenky, G.L. (1981). Electroconvulsive shock (ECS) results in a functional activation of endorphin systems. In H. Emrich (Ed.), The Role of Endorphins in Neuropsychiatry (pp. 142-157). Basel, Switzerland: S. Karger.
16. Holaday, J.W. and Faden, A.I. (1981). Naloxone and thyrotropin releasing hormone have additive effects in reversing endotoxic shock. In H. Takagi et al (Eds.), Advances in Endogenous and Exogenous Opioids (pp. 367-370). Tokyo: Kodansha.

1982:

17. Holaday, J.W. and Faden, A.I. (1982). Endorphins and thyrotropin releasing hormone in shock and trauma. In H. Yoshida, Y. Hagihara, and S. Ebashi (Eds.), Advances in Pharmacology and Therapeutics II, Vol. 1, (pp. 45-55). Oxford: Pergamon Press.
18. Faden, A.I., Jacobs, T.P., and Holaday, J.W. (1982). Neuropeptides and spinal cord injury. In E. Costa and M. Trabucchi (Eds.), Regulatory Peptides: Functional and Pharmacological Aspects (pp. 131-138). New York: Raven Press. (Advances in Biochemical Psychopharmacology 33, 131-138.)

19. Holaday, J.W., D'Amato, R.J., Ruvio, B.A., and Faden, A.I. (1982). Action of naloxone and TRH on the autonomic regulation of circulation. In E. Costa and M. Trabucchi (Eds.), Regulatory Peptides: From Molecular Biology to Function (pp. 353-361). New York: Raven Press. (Advances in Biochemical Psychopharmacology 33, 353-361.)

1983:

20. Holaday, J.W. (1983). Endorphins in shock and spinal injury; therapeutic effects of naloxone and thyrotropin releasing hormone. In Molecular and Cellular Aspects of Shock and Trauma (pp. 167-184). New York: Alan R. Liss.
21. Holaday, J.W. and Faden, A.I. (1983). Spinal shock and injury: experimental therapeutic approaches. In S. Reichard and D. Reynolds (Eds.), Advances in Shock Research 10, 95-98. New York: Alan R. Liss.
22. Holaday, J.W. and Reynolds, D.G. (1983). The role of endogenous opiates in shock: introductory comments. In S. Reichard and D. Reynolds (Eds.), Advances in Shock Research 10, 53-55. New York: Alan R. Liss.
23. Holaday, J. W. (1983). Cardiovascular effects of the endogenous opiate system. In Annual Review of Pharmacology 23, 541-594.
24. Holaday, J.W. (1983). Endogenous opioid systems in shock, neuronal ischemia, and pain: therapeutic effects of naloxone and TRH. In M. Tiengo and M. Cousins (Eds.) Pharmacological Basis of Anesthesiology (pp.213-224). New York: Raven Press.

1984:

25. Holaday, J.W. (1984). Neuropeptides in shock and traumatic injury: sites and mechanisms of action. In Neuroendocrine Perspectives 3, 161-199.
26. Holaday, J.W. & Tortella, F.C. (1984). Multiple opioid receptors: possible physiological functions of μ and δ binding sites in vivo. In E.E. Miller and A.R. Genazzani (Eds.), Central and Peripheral Endorphins: Basic and Clinical Aspects (pp. 237-250). New York: Raven Press.
27. Holaday, J.W., Gilbeau, P.M., Smith, C.G. & Pennington, L.L. (1984). Multiple opioid receptors in the regulation of neuroendocrine responses in the conscious rat and monkey. In G. Delitala et al (Eds.), Opioid Modulation of Endocrine Function (pp.21-31). New York: Raven Press.
28. Belenky, G.L., Tortella, F.C., Hitzemann, R.J. and Holaday, J.W. (1984). The role of endorphin systems in the effects of single and repeated electroconvulsive shock. In B. Lerer, R.D. Weiner and R.M. Belmaker (Eds.), ECS: Basic Mechanisms (pp.89-97). London: John Libbey and Co.
29. Holaday, J.W. (1984). Endogenous opioid systems and autonomic function. In G. Racagni et al (Eds.), Int. Cong. Neuropsychopharmacology (pp. 726-727). New York: Raven Press.

1985:

30. Holaday, J.W., Black, L.B. and Long, J.B. (1985). Neuropeptides in shock and trauma. In B. Chernow (Ed.), Clinics in Critical Care Medicine (pp. 257-284).
31. Holaday, J.W. (1985). Opioid antagonists in septic shock. In R.K. Root and M.A. Sande (Eds.), Septic Shock (pp.117-134). New York: Churchill Livingstone Inc.
32. Holaday, J.W. (1985). Endogenous opioids and their receptors. In Current Concepts, Kalamazoo, MI: Scope Publications, Upjohn.
33. Bernton, E., Frondoza, C., Grzanna, R. and Holaday, J.W. (1985). Effects of naloxone on the growth of LPC-1 plasmacytoma in mice. In N. Herbert Spector (ed.), First

International Workshop on Neuroimmunoimmodulation (pp. 245-248). Bethesda, MD: IWGN Publishers.

1986:

34. Bernton, E., Hartmann, D., Gilbreath, M., Holaday, J. and Meltzer, M.S. (1986). Inhibition of macrophage in vivo activation by pharmacologic blockade of prolactin release. In Leukocytes and Host Defenses (pp. 213-219). New York: Alan R. Liss, Inc.

35. Holaday, J.W., Tortella, F.C., Long, J.B., Belenky, G.L. and Hitzemann, R.J. (1986). Endogenous opioids and their receptors: evidence for involvement in the postictal effects of electroconvulsive shock. In Electroconvulsive Therapy Clinical and Basic Research Issues: Annals of the New York Academy of Science 462, 124-139.
36. Holaday, J.W. (1986). Opioids and other neuropeptides: functional interactions with autonomic systems. In Frederickson, Aprison, Hendrie and Hingtgen (Eds.), Neuronal Control of Bodily Function (pp. 151-182). Kluwer Acad. Pub.
37. Holaday, J.W., Bernton, E.W., Kinney, R.C., Long, J.B. and Malcolm, D.S. (1986). Endogenous opioids and other peptides in shock, spinal trauma and stroke. In A. Gasparetto (Ed.), 2nd Intl. Resuscitation Days, Exerpta Medica International Congress (pp. 45-58). Amsterdam, The Netherlands: Elsevier Science Pub. B.V.
38. Holaday, J.W. and Malcolm, D.S. (1986). Endogenous opioids and their antagonists in endotoxic shock. In W. Marget, W. Lang, E. Gabler-Sandberger (Eds.), 9th International Congress of Infectious and Parasitic Diseases: Bacterial Infections, Antibacterial Chemotherapy vol. 2. Munich, Germany.
39. Holaday, J.W., Tortella, F.C., Meyerhoff, J.L., Belenky, G.L. and Hitzemann, R.J. (1986). Electroconvulsive shock activates endogenous opioid systems: behavioral and biochemical correlates. In Stress-Induces Analgesia: Annals of the New York Academy of Science 467, 249-255.
40. Holaday, J.W., Tortella, F.C., Maneckjee, R. and Long, J.B. (1986). In vivo interactions among opiate receptor agonists and antagonists. In Opiate Receptor Subtypes and Brain Function, NIDA Monograph 71, 173-188.
41. Long, J.B., Kinney, R.C., Malcolm, D.S., Graeber, G.M., and Holaday, J.W. (1986). Intrathecal Dynorphin A (1-13) and (3-13) reduce spinal cord blood flow by non-opioid mechanisms. In Progress in Opioid Research: Proceedings of the International Narcotics Research Conference, NIDA Research Monograph Series 75, 524-526.
42. Tortella, F.C. and Holaday, J.W. (1986). Dynorphin (1-13): in vivo antagonist actions and non-opioid anticonvulsant effects in the rat flurothyl test. In Progress in Opioid Research: Proceedings of the International Narcotics Research Conference, NIDA Research Monograph Series 75, 539-542.
43. Malcolm, D.S., Amir, S. and Holaday, J.W. (1986). Central glucagon antagonizes morphine- and stress-induced antinociception in the mouse. In Progress in Opioid Research: Proceedings of the International Narcotics Research Conference, NIDA Research Monograph Series 75, 539-542.

1987:

44. Holaday, J.W. and Malcolm, D.S. (1987). Opioids and other peptides in respiratory function. In J. Martin, M. Brownstein and D.T. Kreiger (Eds.), Brain Peptides Update,Vol. 1 (pp. 175-192). New York: John Wiley & Sons, Inc.

1988:

45. Holaday, J.W., and Gurll, N.J. (1988). Neuropharmacological mechanisms and approaches to shock therapy. In R.F. Bond, H.R. Adams, I.H. Chaudry (Eds.), Perspectives in Shock Research, Progress in Clinical and Biological Research, Vol. 264 (pp. 307-308). New York: Alan R. Liss Inc.

46. Long, J.B. and Holaday, J.W. (1988). Adrenal corticosteroids in the endogenous regulation of blood-brain barrier permeability: functional implications. In D. Hellhammer, I. Florin and H. Weiner (Eds.), Neuronal Control of Bodily Functions: Basic and Clinical Aspects II - Neurobiological Approaches to Human Disease (pp. 358-369). Lewiston, NY: Hans Huber Publishers.
47. Bernton, E.W., Meltzer, M.S. and Holaday, J.W. (1988). Permissive effects of prolactin on cellular immunity in vivo: implications relating behavioral stress and host defenses. In D. Hellhammer, I. Florin and H. Weiner (Eds.), Neuronal Control of Bodily Functions: Basic and Clinical Aspects II - Neurobiological Approaches to Human Disease (pp. 290-300). Lewiston, NY: Hans Huber Publishers.
48. Cymerman Craig, J., Gruenke, L.D., Klein, F.D., Hitzemann, B.A., Holaday, J.W., Loh, H.L., Braff, D.L., Fischer, A., Glick, I.D., Hartmann, F. and Bissell, D. M. (1988). Development of a method for the determination of chlorpromazine and its major metabolites by gas chromatography/mass spectrometry, and application to biological fluids. In Perspectives in Psychopharmacology: A Collection of Papers in Honor of Earl Usdin (pp. 375-389). New York: Alan R. Liss, Inc.
49. Malcolm, D.S., Holaday, J.W., Chernow, B. and Zaloga, G.P. (1988). Calcium and calcium antagonists in shock and ischemia. In B. Chernow (Ed.) The Pharmacologic Approach to the Critically Ill Patient, Second Edition (pp. 889-900). Baltimore: William and Wilkins.
50. Holaday, J.W. and Malcolm, D.S. (1988). Endogenous opioids and other peptides: evidence for their clinical relevance in shock and CNS injury. In B. Chernow (Ed.) The Pharmacologic Approach to the Critically Ill Patient, Second Edition (pp. 718-732). Baltimore: William and Wilkins.
51. Zaloga, G.P., Malcolm, D.S., Holaday, J.W. and Chernow, B. Glucagon. (1988). In B. Chernow (Ed.) The Pharmacologic Approach to the Critically Ill Patient, Second Edition (pp. 659-670). Baltimore: William and Wilkins.
52. Holaday, J.W., Malcolm, D.S. and Long, J.B. (1988). Endogenous opioids in the pathophysiology of shock: sites of action, autonomic involvement and receptor interactions. In K. Stumpe, A. Faden and K. Kraft (Eds.), Opioid Peptides and Blood Pressure Control (pp. 221-232). New York: Springer-Verlag.

1989:

53. Holaday, J.W., Long, J.B. and Tortella, F.C. (1989). Opioids and stress: effects upon nociception, behavior and autonomic function following ECS, circulatory shock or CNS injury. In Y. Tache, J.E. Morley and M.R. Brown (Eds.), Hans Selye Symposium: Neuropeptides and Stress (pp. 256-275). New York: Springer-Verlag.
54. Holaday, J.W., Bryant, H.U., Kenner, J.R. and Bernton, E.W. (1989). Brain, endocrine and immune interactions: implications in intensive care. In J.W. Holaday and D. Bihari (Eds.), Brain Failure: Series-Update in Intensive Care and Emergency Medicine, Vol. 9 (pp. 1-3). New York: Springer-Verlag.
55. Holaday, J.W. (1989). Role of opioid antagonists in the therapy of septic shock. In K. Reinhart and K. Eyrich (Eds.), Sepsis: An Interdisciplinary Challenge (pp.365-376). New York: Springer-Verlag.
56. Bernton, E.W., Meltzer, M.S. and Holaday, J.W. (1989). Permissive effects of prolactin on cellular immunity in vivo: implications relating to behavioral stress and host

defenses. In D. Hellhammer, I. Florin and H. Weiner (Eds.), Neurobiological Approaches to Human Disease, Vol. 2 (pp.290-300). New York: Hans Huber Publishers.

57. Holaday, J.W. (1989). Opioid peptides: physiological and behavioral effects. In H. Weiner, I. Florin, R. Murison and D. Hellhammer (Eds.), Frontiers of Stress Research, Vol. 3 (pp.309-320). New York: Hans Huber Publishers.

1990:

58. Bryant, H.U., Bernton, E.W. and Holaday, J.W. (1990). Immunomodulatory effects of chronic morphine treatment: pharmacologic and mechanistic studies. In National Institute Drug Abuse Res. Monograph 96, 131-149.
59. Bryant, H.U., Holaday, J.W., Gendelman, H.E., Meltzer, M.S., and Bernton, E.W. (1990). Neuronotrophic effects of granulocyte and macrophage colony stimulating factors. In H.C. Hendrie, L.G. Mendelsohn and C. Readhead (Eds.), Neuronal Control of Bodily Function: Basic and Clinical Aspects, Vol. 5 (pp. 259-264). Toronto: Huber Publishers.
60. Rothman, R.B., Long, J.B., Bykov, V., Rice, K.C., Holaday, J.W. (1990). Site directed affinity ligands as tools to study the phenomenology and mechanisms of morphine-induced upregulation of opioid receptors, In Problems of Drug Dependence, NIDA Research Monograph 95 (pp. 192-198). Proceedings of the 51st Annual Scientific Meeting, Committee on Problems of Drug Dependence, Inc.

1991:

61. Holaday, J.W., Kenner, J.R., Smith, P.F., Bryant, H.U., and Bernton, E.W. (1991). Is prolactin an autocrine cytokine? In Frederickson, McGaugh and Felten (Eds.), Peripheral Signaling of the Brain: Role in Neural-Immune Interactions, Learning and Memory (pp. 243-255). Toronto: Hogrefe & Huber Publishers.
62. Bryant, H.U., Burgess, S.K., Gendelman, H.E., Meltzer, M.S., Holaday, J.W., and Bernton, E.W. (1991). Neuronotrophic activity associated with monocyte growth factors and products of stimulated monocytes. In Frederickson, McGaugh and Felten (Eds.), Peripheral Signaling of the Brain: Role in Neural-Immune Interactions, Learning and Memory (pp. 83-99). Toronto: Hogrefe & Huber Publishers.
63. Bernton, E.W., and Bryant, H.U., Holaday, J.W. (1991). Prolactin and immune function. Psychoneuroimmunology II (pp. 403-428). Academic Press, Inc.
64. Holaday, J.W., Porreca, F., and Rothman, R.B. (1991). Functional coupling among opioid receptor types. In Estafanos (Ed.), Opioids in Anesthesia II (pp.50-60). Butterworth-Heineman.
65. Holaday, J.W., Bryant, H.U., Kenner, J.R., Smith, P.F., and Bernton, E.W. (1991). Dynamic regulation of the endocrine-immune axis. In Advances in NeuroEndocrine Immunology (pp. 1-17). Padova, Italy: Fidia S.p.A.
66. Holaday, J.W. (1991). Neuroendocrine-immune interactions and their relevance to the pharmacology of critical care medicine. In Klinische Wochenschrift (pp.13-19). Heidelberg, Germany: Springer-Verlag.

1992:

67. Holaday, J.W., Gurll, N.J. (1992). Endogenous opioids and opioid antagonists In endotoxic and septic shock: a current perspective. 12th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belguim.

68. Holaday, J.W. (1992). Endogenous opiate peptides in acute illness: experimental and clinical data. In J-M. Boles (Ed.), Conséquences Endocriniennes des États D'Agression

Aiguë: Perspectives en Réanimation (pp. 121-131). Proceedings of the 1992 Spring Symposium - French Society of Intensive Care. Brest, France: Arnette.

69. Holaday, J.W. (1992). Brain, endocrine and immune interactions: implications in intensive care. In J-M. Boles (Ed.), Conséquences Endocriniennes des États D'Agression Aiguë: Perspectives en Réanimation (pp. 153-161). Proceedings of the 1992 Spring Symposium - French Society of Intensive Care. Brest, France: Arnette.

1993:

70. Rothman, R.B., Holaday, J.W., and Porreca, F. (1993). Allosteric coupling among opioid receptors: evidence for an opioid complex. In A. Herz (Ed.), Handbook of Experimental Pharmacology, Vol.104/I Opioids I (pp. 218-237). Heidelberg: Springer-Verlag.
71. Bryant, H.U. and Holaday, J.W. (1993). Opioids in immunologic processes. In A. Herz (Ed.), Handbook of Experimental Pharmacology, Vol.104/II Opioids II (pp. 361-391). Heidelberg: Springer-Verlag.
72. Holaday, J.W., Kenner, J.R., Smith, P.F., Bryant, U.H., and Bernton, E.W. (1993). Neuroendocrine regulation of immune function. In E. Faist, J. Meakins and F. Schildberg (Eds.), Host Defense Dysfunction in Trauma, Shock and Sepsis (pp. 59-65). Heidelberg: Springer-Verlag.
73. Holaday, J., Neugebauer, E., Rixen, D. (in press). Systemic circulatory management of endotoxic shock. In G. Teasdale, E. Hacke and D.F. Hanley (Eds.), Principles and Practice of Neurocritical Care. Baltimore: Williams & Wilkins.

1994

74. Holaday, J.W. (1994) Anterior pituitary hormones and critical illnesses. In B. Chernow (Ed.), The Pharmacologic Approach to the Critically Ill Patient, Third Edition. (pp.890-900). Baltimore: Williams & Wilkins.
75. Holaday, J.W., Nacy, C.A., Neugebauer, E.A. "Alphabet Soup: An Analysis of Mediators of Sepsis". In E. Faist, A.E. Baue and L. Thijs (Eds.), Intensive Care Medicine, 3rd International Congress on the Immune Consequences of Trauma, Shock, and Sepsis Mechanisms and Therapeutic Approaches, Vol. 20, Supplement 1, 1994, (p. S118), 2-5 March 1994, Munich, Germany.

PATENTS

Presently updating

United States

1. Narcotic Antagonists in the Therapy of Shock, Application No. 06/003,699; Filing Date: 01/16/1979; Patent No./Publication No. 4,267,182; Issue Date: 05/12/1981.
2. Narcotic Antagonists in the Therapy of Shock, Application No. 06/248,622; Filing Date: 03/27/1981; Patent No./Publication No. 4,434,168; Issue Date: 02/28/1984.
3. Thyrotropin Releasing Hormone in Therapy of Shock and as a Central Nervous System Stimulant, Application No. 06/252,443; Filing Date: 04/09/1981; Patent No./Publication No. 4,426,378; Issue Date: 01/01/1984.
4. Method of Reducing Serum Levels of Lipoprotein A, Application No. 07/668,304; Filing Date: 03/13/1991; Patent No./Publication No. 5,114,963; Issue Date: 05/19/1992.
5. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/068,717; Filing Date: 05/27/1993.
6. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/271,557; Filing Date: 07/07/1994.
7. Method for Stimulating the Immune System, Application No. 08/315,199; Filing Date: 09/29/1994; Patent No./Publication No. 5,605,884; Issue Date: 02/25/1997.
8. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/467,101; Filing Date: 06/06/1995; Patent No./Publication No. 5,919,459; Issue Date: 07/06/1999.
9. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 60/077,460; Filing Date: 03/10/1998.
10. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Angiogenesis Using Prostate Specific Antigen, Application No. 60/086,586; Filing Date: 05/22/1998.
11. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 09/265,213; Filing Date: 03/10/1999.
12. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 09/266,543; Filing Date: 03/11/1999; Patent No./Publication No. 6,805,865; Issue Date: 10/19/2004.
13. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 09/316,802; Filing Date: 05/21/1999.
14. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 09/413,049; Filing Date: 10/06/1999; Patent No./Publication No. 6,413,513; Issue Date: 07/02/2002.
15. Flow Electroporation Chamber and Method, Application No. 09/707,928; Filing Date: 11/08/2000; Patent No./Publication No. 6,773,669; Issue Date: 08/10/2004.
16. Antiangiogenic Agents, Application No. 60/253,385; Filing Date: 11/27/2000.
17. Angiostatin and Endostatin Binding Proteins and Methods of Use, Application No. 09/873,676; Filing Date: 06/04/2001.
18. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 09/907,402; Filing Date: 07/17/2001; Patent No./Publication No. 6,544,947; Issue Date: 04/08/2003.
19. Apparatus and Method for Flow Electroporation of Biological Samples, Application No. 10/080,272; Filing Date: 02/21/2002; Patent No./Publication No. 7,029,916; Issue Date: 04/18/2006.

20. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 10/131,241; Filing Date: 04/25/2002.
21. Apparatus and Method for Flow Electroporation of Biological Samples, Application No. 10/225,446; Filing Date: 08/21/2002; Patent No./Publication No. 7,141,425; Issue Date: 11/28/2006.
22. Apparatus and Method for Electroporation of Biological Samples, Application No. 10/751,586; Filing Date: 01/05/2004; Patent No./Publication No. 7,186,559; Issue Date: 03/06/2007.
23. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 10/777,998; Filing Date: 02/12/2004.
24. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 10/799,163; Filing Date: 03/12/2004.
25. Flow Electroporation Chamber and Method, Application No. 10/846,729; Filing Date: 05/14/2004; Patent No./Publication No. 2005/0019311; Issue Date: 01/27/2005.
26. Hybrid Opioid Compounds and Compositions, Patent 8,461,171; Filing Date: 06/11/2013.
27. Hybrid Opioid Compounds and Compositions, Application No. 13,891,793; Filing Date: 5/10/2013.
28. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Application No. 13/485,909; Filing Date 05/31/2012
29. Device for Neutralization and Disposal of Pharmaceutical Agents. 61/746,567 (provisional); Filing Date 12/28/2012.
30. Device for Neutralization and Disposal of Pharmaceutical Agents. 61/805,504 (provisional); Filing Date 03/26,2013.
31. Method of Treating Cancer, 61-321-370 (provisional) Filing Date 4/6/2010
32. Methods of Treating Cancer, PCT-US2011-031359, publication # WO 2001/127129 A1 Filing Date 4/6/2011
33. Method of Reducing Serum Levels of Lipoprotein A, Application No. AU 199216411; Filing Date: 03/12/1992; Patent No./Publication No. AU 199216411; Issue Date: 10/21/1992.
34. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 69890/94; Filing Date: 05/26/1994; Patent No./Publication No. 199469890; Issue Date: 12/20/1994.
35. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 60175/99; Filing Date: 05/21/199.
36. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 33972/00; Filing Date: 03/10/2000; Patent No./Publication No. 776,473; Issue Date: 01/06/2005.
37. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2004237888; Filing Date: 12/09/2004; Patent No./Publication No. 2004237888; Issue Date: 07/24/2008.
38. Hybrid Opioids Compound and Compositions, # not yet assigned, Filing date April 12, 2013.

39. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Not Yet Assigned; Filing Date 04/12/2013

Austria

40. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. E 246.513; Issue Date: 08/06/2003.
41. Belgium

42. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
43. Canada

44. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2,163,652; Filing Date: 11/23/1995.
45. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 2,327,541;
Filing Date: 05/21/1999.
46. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2,364,503; Filing Date: 03/10/2000.
47. Methods of Treating Cancer (Nat'l Phase Pending) Publication No.. 201180019660.9 Filing Date: 4/6/2011

Denmark

48. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

49. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
50. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 99 953 281.5;
Filing Date: 05/21/1999.
51. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 00 912209.4; Filing Date: 03/10/2000.
52. Methods of Treating Cancer (Nat'l Phase – PCT Pending) 11766628.9; EP 2,555,627 Filing Date 4/6/2011

53. France

54. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

55. Germany

56. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. 694 33 013.2-08; Issue Date: 08/06/2003.
57. Hong Kong

58. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 98115900; Filing Date: 12/28/1999.
59. Ireland

60. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

61. Italy

62. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. 28176 BE/2003; Issue Date: 08/06/2003.
63. Japan

64. Flow Electroporation Chamber and Method, Application No. 1996-527748;
Filing Date: 03/11/1996; Patent No./Publication No. 3859709; Issue Date: 12/20/2006.
65. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 7-500957; Filing Date: 05/26/1994.
66. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 2000-550445;
Filing Date: 11/20/2000.
67. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2000-603708; Filing Date: 09/11/2001.
68. Flow Electroporation Chamber and Method, Application No. 2006-202504;
Filing Date: 07/25/2006; Patent No./Publication No. 4171755; Issue Date: 10/29/2008.
69. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2007-191910; Filing Date: 07/24/2007.
70. Methods of Treating Cancer Pending 2013-503875 Publication No WO 2001/127129 A1, Nat'l Phase-PCT Filing Date: 4/6/2011

71. Netherlands

72. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
73. South Korea

74. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 7013022/2000; Filing Date: 05/21/1999.
75. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 7011491/2001; Filing Date: 09/10/2001.
76. Flow Electroporation Chamber and Method, Application No. 1997706255; Filing Date: 09/08/1997; Patent No./Publication No. 1998702848; Issue Date: 08/05/1998.

77. Spain

78. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
79. Switzerland

80. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

81. United Kingdom

82. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

WIPO

83. Method of Reducing Serum Levels of Lipoprotein A, Application No. PCT/US92/002041; Filing Date: 03/12/1992; Patent No./Publication No. WO 92/016204; Issue Date: 10/01/1992.
84. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. PCT/US94/005927 ; Filing Date: 05/26/1994; Patent No./Publication No. WO 94/027635; Issue Date: 12/08/1994.
85. Flow Electroporation Chamber and Method, Application No. PCT/US96/003211; Filing Date: 03/11/1996; Patent No./Publication No. WO 96/028199; Issue Date: 09/19/1996.
86. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. PCT/US99/11418; Filing Date: 05/21/1999; Patent No./Publication No. WO 99/60984; Issue Date: 12/02/1999.

87. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. PCT/US00/06320; Filing Date: 03/10/2000; Patent No./Publication No. WO 00/53219; Issue Date: 09/14/2000.
88. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. PCT/US00/27759; Filing Date: 10/06/2000.
89. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Application No. PCT/US12/40330; Filing Date 05/31/2012
90. Hybrid Opioid Compounds and Compositions, Application No. PCT/US12/24482; Filing Date: 02/09/2012.

PATENTS

Presently updating

United States

1. Narcotic Antagonists in the Therapy of Shock, Application No. 06/003,699; Filing Date: 01/16/1979; Patent No./Publication No. 4,267,182; Issue Date: 05/12/1981.
2. Narcotic Antagonists in the Therapy of Shock, Application No. 06/248,622; Filing Date: 03/27/1981; Patent No./Publication No. 4,434,168; Issue Date: 02/28/1984.
3. Thyrotropin Releasing Hormone in Therapy of Shock and as a Central Nervous System Stimulant, Application No. 06/252,443; Filing Date: 04/09/1981; Patent No./Publication No. 4,426,378; Issue Date: 01/01/1984.
4. Method of Reducing Serum Levels of Lipoprotein A, Application No. 07/668,304; Filing Date: 03/13/1991; Patent No./Publication No. 5,114,963; Issue Date: 05/19/1992.
5. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/068,717; Filing Date: 05/27/1993.
6. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/271,557; Filing Date: 07/07/1994.
7. Method for Stimulating the Immune System, Application No. 08/315,199; Filing Date: 09/29/1994; Patent No./Publication No. 5,605,884; Issue Date: 02/25/1997.
8. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 08/467,101; Filing Date: 06/06/1995; Patent No./Publication No. 5,919,459; Issue Date: 07/06/1999.
9. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 60/077,460; Filing Date: 03/10/1998.
10. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Angiogenesis Using Prostate Specific Antigen, Application No. 60/086,586; Filing Date: 05/22/1998.
11. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 09/265,213; Filing Date: 03/10/1999.
12. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 09/266,543; Filing Date: 03/11/1999; Patent No./Publication No. 6,805,865; Issue Date: 10/19/2004.

13. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 09/316,802; Filing Date: 05/21/1999.
14. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 09/413,049; Filing Date: 10/06/1999; Patent No./Publication No. 6,413,513; Issue Date: 07/02/2002.
15. Flow Electroporation Chamber and Method, Application No. 09/707,928; Filing Date: 11/08/2000; Patent No./Publication No. 6,773,669; Issue Date: 08/10/2004.
16. Antiangiogenic Agents, Application No. 60/253,385; Filing Date: 11/27/2000.
17. Angiostatin and Endostatin Binding Proteins and Methods of Use, Application No. 09/873,676; Filing Date: 06/04/2001.
18. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 09/907,402; Filing Date: 07/17/2001; Patent No./Publication No. 6,544,947; Issue Date: 04/08/2003.
19. Apparatus and Method for Flow Electroporation of Biological Samples, Application No. 10/080,272; Filing Date: 02/21/2002; Patent No./Publication No. 7,029,916; Issue Date: 04/18/2006.
20. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Cancer Markers, Application No. 10/131,241; Filing Date: 04/25/2002.
21. Apparatus and Method for Flow Electroporation of Biological Samples, Application No. 10/225,446; Filing Date: 08/21/2002; Patent No./Publication No. 7,141,425; Issue Date: 11/28/2006.
22. Apparatus and Method for Electroporation of Biological Samples, Application No. 10/751,586; Filing Date: 01/05/2004; Patent No./Publication No. 7,186,559; Issue Date: 03/06/2007.
23. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 10/777,998; Filing Date: 02/12/2004.
24. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 10/799,163; Filing Date: 03/12/2004.
25. Flow Electroporation Chamber and Method, Application No. 10/846,729; Filing Date: 05/14/2004; Patent No./Publication No. 2005/0019311; Issue Date: 01/27/2005.
26. Hybrid Opioid Compounds and Compositions, Patent 8,461,171; Filing Date: 06/11/2013.
27. Hybrid Opioid Compounds and Compositions, Application No. 13,891,793; Filing Date: 5/10/2013.
28. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Application No. 13/485,909; Filing Date 05/31/2012
29. Device for Neutralization and Disposal of Pharmaceutical Agents. 61/746,567 (provisional); Filing Date 12/28/2012.
30. Device for Neutralization and Disposal of Pharmaceutical Agents. 61/805,504 (provisional); Filing Date 03/26,2013.
31. Method of Treating Cancer, 61-321-370 (provisional) Filing Date 4/6/2010

32. Methods of Treating Cancer, PCT-US2011-031359, publication # WO 2001/127129 A1 Filing Date 4/6/2011
33. Method of Reducing Serum Levels of Lipoprotein A, Application No. AU 199216411; Filing Date: 03/12/1992; Patent No./Publication No. AU 199216411; Issue Date: 10/21/1992.
34. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 69890/94; Filing Date: 05/26/1994;
Patent No./Publication No. 199469890; Issue Date: 12/20/1994.
35. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 60175/99; Filing Date: 05/21/199.
36. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 33972/00; Filing Date: 03/10/2000;
Patent No./Publication No. 776,473; Issue Date: 01/06/2005.
37. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2004237888; Filing Date: 12/09/2004;
Patent No./Publication No. 2004237888; Issue Date: 07/24/2008.
38. Hybrid Opioids Compound and Compositions, # not yet assigned, Filing date April 12, 2013.
39. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Not Yet Assigned; Filing Date 04/12/2013

Austria

40. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994;
Patent No./Publication No. E 246.513; Issue Date: 08/06/2003.
41. Belgium

42. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
43. Canada

44. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2,163,652; Filing Date: 11/23/1995.
45. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 2,327,541;
Filing Date: 05/21/1999.
46. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2,364,503; Filing Date: 03/10/2000.
47. Methods of Treating Cancer (Nat'l Phase Pending) Publication No.. 201180019660.9 Filing Date: 4/6/2011

Denmark

48. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

49. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
50. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 99 953 281.5; Filing Date: 05/21/1999.
51. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 00 912209.4; Filing Date: 03/10/2000.
52. Methods of Treating Cancer (Nat'l Phase – PCT Pending) 11766628.9; EP 2,555,627 Filing Date 4/6/2011

53. France

54. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

55. Germany

56. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 694 33 013.2-08; Issue Date: 08/06/2003.
57. Hong Kong

58. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 98115900; Filing Date: 12/28/1999.
59. Ireland

60. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

Italy

61. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 28176 BE/2003; Issue Date: 08/06/2003.
62. Japan

63. Flow Electroporation Chamber and Method, Application No. 1996-527748; Filing Date: 03/11/1996; Patent No./Publication No. 3859709; Issue Date: 12/20/2006.

64. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 7-500957; Filing Date: 05/26/1994.
65. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 2000-550445; Filing Date: 11/20/2000.
66. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2000-603708; Filing Date: 09/11/2001.
67. Flow Electroporation Chamber and Method, Application No. 2006-202504; Filing Date: 07/25/2006; Patent No./Publication No. 4171755; Issue Date: 10/29/2008.
68. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 2007-191910; Filing Date: 07/24/2007.
69. Methods of Treating Cancer Pending 2013-503875 Publication No WO 2001/127129 A1, Nat'l Phase-PCT Filing Date: 4/6/2011

70. Netherlands

71. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
72. South Korea

73. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. 7013022/2000; Filing Date: 05/21/1999.
74. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 7011491/2001; Filing Date: 09/10/2001.
75. Flow Electroporation Chamber and Method, Application No. 1997706255; Filing Date: 09/08/1997; Patent No./Publication No. 1998702848; Issue Date: 08/05/1998.

76. Spain

77. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.
78. Switzerland

79. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

80. United Kingdom

81. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders, Application No. 94918667; Filing Date: 05/26/1994; Patent No./Publication No. 0702563; Issue Date: 08/06/2003.

WIPO

82. Method of Reducing Serum Levels of Lipoprotein A,
Application No. PCT/US92/002041; Filing Date: 03/12/1992;
Patent No./Publication No. WO 92/016204; Issue Date: 10/01/1992.
83. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders,
Application No. PCT/US94/005927 ; Filing Date: 05/26/1994;
Patent No./Publication No. WO 94/027635; Issue Date: 12/08/1994.
84. Flow Electroporation Chamber and Method, Application No. PCT/US96/003211;
Filing Date: 03/11/1996; Patent No./Publication No. WO 96/028199;
Issue Date: 09/19/1996.
85. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. PCT/US99/11418;
Filing Date: 05/21/1999; Patent No./Publication No. WO 99/60984;
Issue Date: 12/02/1999.
86. Compositions and Methods for Treating Cancer and Hyperproliferative Disorders,
Application No. PCT/US00/06320; Filing Date: 03/10/2000; Patent No./Publication No. WO 00/53219; Issue Date: 09/14/2000.
87. Compositions and Methods for Inhibiting Endothelial Cell Proliferation and Regulating Angiogenesis Using Serine Proteases, Application No. PCT/US00/27759; Filing Date: 10/06/2000.
88. Methods and Compositions Comprising Sequential Administration of Opioid Receptor Agonists. Application No. PCT/US12/40330; Filing Date 05/31/2012
89. Hybrid Opioid Compounds and Compositions, Application No. PCT/US12/24482;
Filing Date: 02/09/2012.